Orion/Novartis's Stalevo fails in early stage Parkinson's disease
This article was originally published in Scrip
Orion and Novartis's Parkinson's disease treatment, Stalevo (a combination formulation of carbidopa, levodopa and entacapone) has failed to meet the primary endpoint of a Phase IV study in patients when used as a first-line levodopa therapy to delay the onset of motor complications in early stage Parkinson's.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.